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Abstract
This review will focus on the proposed second mode of testosterone action (now termed non-genomic) that appears to occur
independently of the traditional transcriptional mechanism in
mammalian skeletal muscle cells which may enhance skeletal
muscle contractile properties. This mechanism of testosterone
action differs from the traditional pathway, originating at the
cell membrane, having a rapid onset of action, requiring second
messengers to execute its effects and is insensitive to inhibitors
of traditional androgen receptor action, transcription and protein
synthesis. Importantly, unlike the traditional action of testosterone in skeletal muscle, this non-genomic pathway is shown to
have a direct acute effect on calcium-dependent components
important for the contractile process. The changes within the
contractile apparatus may enhance the ability of the muscle to
produce explosive power during athletic performance. Rapid
increases in Inositol triphosphate mass and calcium release from
the sarcoplasmic reticulum have been reported in rodent skeletal
muscle cells, and a rapid androgen (dihydrotestosterone)induced increase in peak force production has been recorded in
intact rodent skeletal muscle fibre bundles while showing increases in the activity of the Ras/MAP/ERK mediated pathway.
Because the non-genomic action of testosterone is enhanced
during increases in exposure to testosterone and is acute in its
action, implications for athletic performance are likely greater in
females than males due to natural fluctuations in circulating
testosterone levels during the female menstrual cycle, reproductive pathology, and changes induced by hormonal contraceptive
methods. Research should be undertaken in humans to confirm a
pathway for non-genomic testosterone action in human skeletal
muscle. Specifically, relationships between testosterone fluctuations and physiological changes within skeletal muscle cells and
whole muscle exercise performance need to be examined.
Key words: Calcium, fatigue, female, rapid, power, androgen.

Introduction
During exercise, the endocrine system secretes hormones
into the bloodstream to regulate metabolism (McKeever,
2002; Mastorakos et al., 2005) and maintain the integrity
of the body’s internal environment. Therefore the control
of hormone secretion must be complex and sensitive to
adapt quickly to changing biological stresses within the
body during exercise. Testosterone is an anabolic steroid
hormone that is found in the bloodstream in 3 forms;
strongly bound to sex hormone binding globulin (SHBG)
(~70%), weakly bound to albumin (~30%) and unbound
(~0.5-3%). Traditionally, the physiological function of
testosterone in skeletal muscle tissue is the maintenance
and increase of skeletal muscle mass (hypertrophy)

through genomic (long-term, transcriptional) mechanisms
and the subsequent indirect increase in muscle strength
(Cardinale and Stone, 2006; Griggs et al., 1989). However, steroid hormones including testosterone are now
shown to elicit rapid actions (within seconds to minutes)
in a number of cell types (Benten et al., 1997; 1999a;
Ceballos et al., 1999; Estrada et al., 2003; Furukawa and
Kurokawa, 2008; Hamdi and Mutungi, 2010; Jones et al.,
2004; Waldkirch et al., 2008) through non-genomic
mechanisms (short-term, non-transcriptional) (Benten et
al., 1999b). The complex interaction of acute and long
term steroid adaptation has however, yet to be described.
While testosterone’s significant genomic action in skeletal
muscle is well described, (Bhasin et al., 2005; SinhaHikim et al., 2002; 2003; Urban et al., 1995) little attention has been directed towards such non-genomic actions
of testosterone in skeletal muscle. This article will discuss
a mode of non-genomic action in skeletal muscle and
proposed implications for sporting performance specifically for female athletes.
What are non-genomic steroid actions?
Non-genomic actions of steroid hormones are those steroid mediated actions in which gene transcription is not
directly implicated (shown through insensitivity to inhibitors of transcription and protein synthesis), involves
second messenger participation and are rapid in action
(within seconds to minutes). As described further in this
review, non-genomic actions differentiate themselves
from genomic mechanisms in the first instance by the
binding of the steroid to an androgen receptor located on
the cell-membrane or by linking with a plasma membrane
receptor associated with a Pertussis toxin (PTX)-sensitive
G protein (Vicencio et al., 2006) rather than binding with
the traditional androgen receptor in the cytoplasm of the
cell before being translocated into the nucleus. Unlike the
genomic effects of steroid hormones, non-genomic effects
require the constant presence of the hormone. Once the
hormone subsides from the tissue, so too will the nongenomic effects.
Evidence for a non-traditional testosterone action
has been documented regularly in tissues other than skeletal muscle. In the early 1990s, a rapid effect of testosterone on calcium mobility in T-cells, that was initiated at
the cell membrane was reported (Benten et al., 1999b),
suggesting there was an alternative rapid biological response to testosterone. Similarly, cardiac myocytes from
adult rats exposed to testosterone rapidly (1-7 minutes)
induced an increase in levels of intracellular calcium
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released from intracellular stores through Inositol
trisphosphate (IP3) receptors. This calcium response was
not linked with the intracellular androgen receptor, but
instead through activation of a plasma membrane receptor
associated with a (PTX)-sensitive G protein (Vicencio et
al., 2006). Similarly again, testosterone rapidly stimulated
increases in calcium concentration in rat osteoblasts
(within 5 s via enhanced calcium influx) and increased
calcium mobilisation from the endoplasmic reticulum, as
well as increasing IP3 formation within 10 s (Lieberherr
and Grosse, 1994). IP3 is used for signal transduction in
biological cells via the release of calcium from the endoplasmic reticulum via the IP3 receptor (IP3R). Testosterone appears to exert these rapid actions through an unidentified G-protein (guanine nucleotide-binding proteins
communicate signals from hormones extracellular that
then regulate changes intracellular) located on the cell
membrane (Benten et al., 1999a; Vicencio et al., 2006).
Rapid actions of testosterone in skeletal muscle
have been less researched compared with other tissues
such as cardiac muscle and bone (Benten et al., 1997;
1999a) as outlined above. However, the few papers investigating non-genomic testosterone action in skeletal muscle suggest testosterone is capable of producing similar
rapid (within 2 min) effects in skeletal muscle cells
(Estrada 2000; 2003; Hamdi and Mutungi, 2010). To date,
non-genomic testosterone action in skeletal muscle has
only been investigated in isolated rodent cells and fibre
bundles, with most evidence originating from two studies
by Estrada et al (Estrada et al., 2000; 2003). These two
studies isolated myotubes and achieved a response to 100
nM of testosterone in 70% of cells. Supraphysiological
levels of testosterone (100 nM) at the single-cell level in
primary myotubes induced a relatively fast (<2 min) tran-
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sient increase in intracellular calcium, which was frequently accompanied by oscillations and a transient increase in the mass of IP3 to threefold the basal levels
within 45 s. Both unbound and albumin-bound testosterone initiated this non-genomic action. These results are
similar to those previously identified in other tissue cells
(cardiac myocytes, T-Cells, osteoblasts). These results
provided support for a G-protein-linked receptor at the
plasma membrane, and an IP3/calcium, Ras/MEK/ERK
mediated pathway. ERK1/2 increased in response to testosterone in a transient and dose-dependent (50-100nM)
manner, while G-protein inhibitors blocked the fast rise in
calcium and IP3 and thus the fast effect of testosterone.
Therefore, the signal transduction mechanisms of nongenomic actions within skeletal muscle are likely regulated by second messengers such as intracellular calcium
and IP3 (Estrada et al., 2000; Estrada et al., 2003). These
non-genomic signal pathways have been previously identified in the action of testosterone, aldosterone, (Estrada et
al., 2000) and 17-β-estradiol (Morley and Whitfield et al.,
1992) and are outlined in Figure 1.
The only study of rapid steroid action in intact
skeletal muscle fibres was recently published by Hamdi
and Mutangi (2010). This study used intact isolated skeletal muscle fibres from the extensor digitorum longus
(predominantly fast-twitch) and soleus (predominantly
slow twitch) muscles of adult male and female mice. Like
the previous studies, this study used formerly published
methods to investigate the effects of steroid hormones on
maximum isometric force. Physiological concentrations
of dihydrotestosterone (DHT) (630 pg·ml-1), significantly
increased force produced in both twitch and titanic contractions in fast twitch fibres. A significant 24% increase
in maximum isometric tension in fast twitch fibres

Figure 1. Possible non-genomic pathway/action of testosterone in skeletal muscle.
Testosterone (T) attaches to a traditional androgen receptor (AR) located at the cell membrane, coupled with a PTX-sensitive G-protein that
activates phospholipase C (PLC). This in turn increases IP3 levels, which are liberated and diffuse to receptors (IP3R) on the sarcoplasmic
reticulum (SR). This in turn increases intracellular calcium levels through the release of calcium from the SR. A possible calcium-induced
activation of the Ras/ERK phosphorylation cascade may occur, resulting in transcription of DNA, which is then expressed as proteins.
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in male mice and a 30% increase in female mice, though
not statistically different from each other, suggests it may
be appropriate to investigate potential gender differences
in non-genomic steroid action. Testosterone however, had
no effect on either twitch or tetanic contractions in either
fast or slow twitch muscle in intact rodent muscle fibre
bundles (Hamdi and Mutungi, 2010). In parallel with the
increases in maximum isometric force seen with exposure
to DHT, physiological concentrations of DHT increased
phosphorylation of ERK1/2 by 2-3 fold in both fibre types
adding support for a non-genomic androgen
RAS/MAP/ERK mediated pathway. Testosterone increased ERK1/2 phosphorylation in slow twitch fibres
only.
While the aforementioned animal studies provide
evidence for a non-genomic mechanism, the ability to
deduce human effects from rodent studies is unclear. It is
therefore important that human research be undertaken to
provide evidence for a non-genomic steroid action in
human skeletal muscle. Based on the current
understanding of non-genomic testosterone action, we
suggest that testosterone may be able to produce an
increase in intracellular calcium levels and calcium
mobility within the human skeletal muscle cell. This may
increase the sensitivity of the contractile elements to calcium, which could increase the speed of myosin head
binding and/or the force at which the myosin head pulls,
such that more force is produced per contraction.
Combined, these effects would likely result in greater
whole muscle power production (refer to Figure 1).
Although current research provides a substantiated basis
for this theory (Estrada et al., 2000; 2003; Hamdi and
Mutungi, 2010), it is vital that research in human skeletal
muscle is undertaken to provide evidence to support both
the molecular and physiological undertones of this theory.
Until further research is undertaken, implications for
athletic performance will remain speculative.
Testosterone and athletic performance
From testosterone supplementation studies in males (3
mg·kg-1·wk-1 for 12 wk) (Griggs et al., 1989) and (600
mg·wk-1 for 10 wk), (Bhasin et al., 1996) the traditional
(transcriptional) action of testosterone demonstrates the
ability to increase protein synthesis (27%), (Griggs et al.,
1989) fat free mass (6.1 ± 0.6 kg ), (Bhasin et al., 1996)
muscle mass (20%), (Griggs et al., 1989) muscle size
(triceps brachii 501 ± 104 mm2, quadriceps 1174 ± mm2)
(Bhasin et al., 1996) and strength (bench press 22 ± 2 kg,
squat 38 ± 4 kg) (Bhasin et al., 1996). Subsequently testosterone was officially listed as a banned substance in
athletic events. While chronic testosterone supplementation can increase strength; (Bhasin et al., 1996) power or
counter-movement jump height has also been shown to
positively correlate with acute natural levels (0.62 ± 0.06
ng·ml-1 and 6.49 ± 0.37 ng·ml-1) of testosterone (r = 0.061,
p<0.001) in female and male elite athletes, respectively
(Cardinale and Stone, 2006). Natural basal testosterone
levels and counter-movement jump height are higher in
explosive athletes, such as sprinters, and lowest in endurance athletes such as cross-country skiers (Bosco, 1998).
Given testosterone’s dual mechanisms (i.e., genomic and

365

non-genomic action), natural testosterone levels may
prove to be more important in the ability to produce acute
explosive power; a variable that is a determinant of performance in sprint, jumping and throwing events (Bourdin
et al., 2010; Hori et al., 2008; Sleivert and Taingahue,
2004; Van Ingen Schenau et al., 1990) than previously
thought.
Fatigue hypothesis: How the non-genomic action of
testosterone may counteract fatigue
Calcium is an important metabolite in muscle contraction,
with both the concentration surrounding the myofilaments
and the sensitivity of the myofilaments to calcium important for the production of force by the individual crossbridges (maximum calcium activated force). Intensive and
repetitive contraction of skeletal muscle causes a decline
in peak performance (i.e. fatigue) characterized by reduced force production, decreased shortening velocity,
and delayed relaxation of the muscle following contraction (Bigland-Ritchie et al., 1979; Edman and Mattiazzi,
1981; Haan et al., 1989; Jones et al., 1979; Milner-Brown
and Miller, 1986; Westerblad and Lännergren, 1991;
Cheng and Rice, 2010). One principal theory of skeletal
muscle fatigue is characteristic changes in calcium regulation and sensitivity that occur during the decline in performance (Kabbara and Allen, 1999).
Previous research provides evidence that during fatiguing muscle contraction there is a decline in calcium
transport; a decline in sarcoplasmic reticulum calcium
release (Kabbara and Allen, 1999; Ward et al., 1998;
Westerblad and Allen, 1991) and/or a reduction in the
sensitivity of the contractile apparatus to calcium (Godt
and Nosek, 1989; Westerblad and Allen, 1993). Both
scenarios would result in impaired excitation-contraction
coupling such that less force is generated for each individual membrane excitation.
A possible protective effect of testosterone against
skeletal muscle fatigue was suggested when Bosco et al.
(2000) investigated neuromuscular activity and hormonal
profile following an acute resistance exercise session in
male and female sprint athletes. Full squat power decreased by 10% at the end of the session in males only.
EMG/power ratio calculated in the half squat test were
decreased in both males and females, but only reached
significance in males (p <0.05). Levels of circulating
testosterone, cortisol and luteinising hormone were significantly lower post exercise in males only, while a negative correlation (r = -0.61) was found between change in
testosterone concentration and EMG/power ratio in half
squat performance in both groups. Bosco et al. (2000)
suggested adequate testosterone levels may compensate
for or offer protection against the effect of fatigue in fasttwitch muscle fibres by ensuring a better neuromuscular
efficiency (Bosco et al., 2000).
We therefore propose, based on results of prior
non-genomic testosterone research, that acute elevations
in testosterone concentration (such as those during the
female menstrual cycle) may be able to reduce or compensate the effects of fatigue in fast-twitch fibres. Due to
non-genomic rapid increases in intracellular calcium
levels and increased mobilisation of calcium from the
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sarcoplasmic reticulum, testosterone may reduce or protect against impaired excitation-contraction coupling
during repeated high-intensity muscle contraction. However, gender differences in hormonal changes, notably
testosterone following squat exercise reported by Bosco et
al., (Bosco et al., 2000) suggest future research should
investigate if there are indeed gender specific responses in
non-genomic testosterone action.
Specific importance of testosterone for female athletes
Testosterone levels have often been difficult to accurately
measure in females due to the combined challenge of both
the naturally low levels of circulating testosterone coupled with low sensitivity and precision of assays. Previous studies have however shown that circulating testosterone fluctuates throughout the menstrual cycle (Judd
and Yen, 1973; Sinha-Hikim et al., 1998). Serum total
and free testosterone levels in the luteal and follicular
phases are not significantly different from each other, but
an approximate 30-45% pre-ovulatory increase in both
total and free testosterone roughly three days prior to the
luteinising hormone peak was recorded in two separate
studies investigating testosterone levels across a full menstrual cycle (Judd and Yen, 1973; Sinha-Hikim et al.,
1998). However, even though a clear peak in both total
and free testosterone was shown in these two studies, no
studies have yet to specifically investigate changes in
muscle strength, explosive power or fatigue when testosterone levels are peaked, which could prove an important
measure as previous studies have shown strong positive
correlations with acute natural testosterone concentration
and acute power performance such as counter-movement
jump height.
Influence of oral contraceptives
Combined hormonal contraceptives prevent ovulation as
their primary mechanism of action (Rivera and Yacobson
et al., 1999). This elimination of ovulation also eliminates
the natural peaking in testosterone prior to the luteinizing
hormone surge. Oral estrogens ingested in common varieties of the oral contraceptive pill, can have significant
consequences on circulating free testosterone levels
(Edwards and O'Neal, 2009; Raj et al., 1983; Rickenlund
et al., 2004; Thorneycroft et al., 1999; Van der Vange et
al., 1990; Wiegratz et al., 1995; 2003a). Oral estrogens
can increase the levels of sex hormone binding globulin
(Campagnoli et al., 1993; Thorneycroft et al., 1999;
Wiegratz et al., 1995; 2003a), which binds to testosterone
making it biologically unavailable thus reducing the ratio
of circulating free testosterone to total testosterone.
Progestin’s can also influence circulating testosterone levels in females, (Gordon et al., 1970) Medroxyprogesterone, a synthetic version of the naturally synthesized
human progesterone (often used in oral contraceptives)
decreases the production rate of testosterone, likely due to
the inhibition of pituitary secretion of luteinizing hormone
and may increase the rate of removal of testosterone from
the circulation (Gordon et al., 1970) (Palatsi et al., 1984;
Wiegratz et al., 2003b). Along with the elimination of the
peak in testosterone during the cycle, and reductions in
total testosterone concentration, oral contraceptives may,
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in our opinion, affect genomic and non-genomic actions
of testosterone, reducing optimal hormonal physiology for
elite female athletic performance.
The potential impact of the menstrual cycle on anaerobic performance has received less attention than the
impact on aerobic variables. There is a lack of consensus
on whether sex hormone fluctuations have an influence on
anaerobic performance, with some studies concluding
performance is unaffected by menstrual cycle phase,
(Doolittle and Engebretsen, 1972; Giacomoni et al., 2000;
Lebrun, 1993; 1994; Lebrun et al., 1995) and others reporting differences in anaerobic performance variables
with menstrual cycle phase (Davies et al., 1991;
Masterson, 1999; Wearing et al., 1972). The strength of
the research looking at anaerobic performance and sex
hormones is faltered by a lack of experimental controls,
including variation in the determination of cycle phase
(hormonal assay vs. body temperature), unclear subject
selection criteria, and differing measures of performance
(sprinting vs. jumping vs. swimming and acute vs. repeated efforts). There is yet no published research on the
effect of menstrual cycle hormones on anaerobic/power
variables in elite female athlete populations.
Studies in which oral contraceptive users were
compared with eumenorrheic females have reported a
trend towards lower strength across an oral contraceptive
cycle compared with a natural cycle. As well, a complete
reduction in the natural fluctuation of testosterone and
strength often seen with a natural cycle has been shown in
women using an oral contraceptive (Phillips et al., 1996;
Sarwar et al., 1996). There is little research that has specifically looked at the effect of the menstrual cycle or oral
contraceptives on explosive power in female athletes.
However, one study examined team sport performance
variables during an oral contraceptive cycle (Rechichi and
Dawson, 2009), with the only significant difference
found in drop jump height in the late withdrawal phase
(end of the sugar pills), where a reduced drop jump height
coincided with increased serum estrogen levels (Rechichi
and Dawson, 2009). It is possible that changes may have
occurred in performance variables in females with a natural menstrual cycle due to the fluctuations in circulating
testosterone; however, although testosterone is known to
reach a peak during the menstrual cycle, no study has
specifically investigated athletic performance at this time.
Furthermore, there are no studies available that have conducted performance tests every day of the menstrual cycle
to ensure all hormonal fluctuations are investigated. In
spite of this, due to testosterone’s correlation with explosive power and evidence of a non-genomic testosterone
action in skeletal muscle, individual female athletes
whose events require strength or power may benefit from
using non-hormonal based contraceptive methods.
Polycystic ovarian syndrome and other menstrual
disorders: A physiological advantage?
Previously, oligomenorrhea in exercising women was
seen as a symptom of menstrual disorders, secondary in
response to metabolic perturbations due to extreme energy deficit (often seen in endurance runners and associated with leanness) (Rosetta et al., 1998; Sanborn et al.,
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1982; Torstveit and Sundgot-Borgen, 2005). However,
with the potential for oligomenorrhea to be associated
with hyperandrogenism [particularly increased levels of
testosterone outside (or within the higher range) of the
physiological limits for normally menstruating women]
many athletic women suffering from oligomenorrhea may
not, as expected, present with symptoms of energy deficit.
Therefore, our opinion is that the perception that female
athletes who present with oligomenorrhea are most likely
to be experiencing extreme energy deficit, may be unfounded.
Although research into the prevalence of hyperandrogenism and polycystic ovarian syndrome in athletic
populations is scarce, the available data suggest that the
most common diagnosis of menstrual disturbance in
Olympic athletes (Hagmar and Berglund et al., 2009) and
women in sports where muscle mass is advantageous or
non-detrimental to performance (Lebrun, 1994;
Masterson, 1999) is polycystic ovarian syndrome. It may
be that women with polycystic ovarian syndrome or hyperandrogenism are inherently attracted to and succeed in
athletic activities. This suggests that oligomenorrhea is
also likely to be a polycystic ovarian syndrome or metabolic syndrome symptom in athletic women, as opposed
to an exercise-induced trait per se. We suggest that polycystic ovarian syndrome may be a competitive advantage
due to the proposed dual mechanism of testosterone
(long-term effects on muscle strength and size, and a
rapid acute effect on contractile efficiency).
Further research is needed to confirm whether
acute testosterone fluctuations seen during a natural menstrual cycle or heightened levels seen in conditions such
as polycystic ovarian syndrome are significant enough to
result in a greater efficiency of the skeletal muscle to
produce force/power. Polycystic ovarian syndrome or
hyperandgrogenism could lead to a physiological advantage for female athletes, especially those competing in
athletic events that require rapid and/or forceful movements.
Non-genomic actions of estrogen
While this review focuses on the specific role of nongenomic testosterone action in skeletal muscle and its
effects within the contractile compartment of skeletal
musculature it is within the scope of this article to briefly
discuss the potential effects of a subsidiary non-genomic
action of another prominent sex hormone that fluctuates
throughout the female menstrual cycle, estrogen.
While ageing, muscle wasting and pathology research support a role for estrogens in skeletal muscle,
particularly in females it is likely that the prevention of
strength loss through estrogen hormone replacement therapy is likely a genomic or transcriptional mechanism
rather than a rapid non-transcriptional mechanism. As this
review is also focusing on the effects of testosterone on
the contractile apparatus it seems pertinent to discuss
those findings in rodent studies that indicate estrogen can
influence the force generating capacity of skeletal muscle
not by maintaining size of individual fibres but by maintaining the integrity and ability of individual fibres to
generate force. This idea is supported by Wattanaperm-

pool et al. (1999) who measured cross sectional area
(CSA) and the peak isometric tension of isolated rat soleus muscle fibres 10 and 14 wk post ovariectomy. While
CSA was not reduced following ovariectomy, CSA was
significantly increased compared with non-ovariectomy
controls at 14 wk, peak tension was significantly lower in
ovariectomised rats compared with sham-operate controls
in both 10-wk (~19%) and 14 wk (~20%) post ovariectomy. These results show that fibres from ovariectomised
rats were not weaker due to their smaller size but rather
there was a deficit in the contractile apparatus likely due
to the absence of estrogen that resulted in a reduced ability to produce force.
Similarly to testosterone, non-genomic estrogen action has been regularly identified in tissues other than
skeletal muscle (Morley et al., 1992; Rubio-Gayosso and
Sierra-Ramirez et al., 2000; Watson et al., 2008; Younglai
et al., 2005). The most regularly reported non-genomic
effect of androgen exposure is a rapid (within seconds)
enhancement in intracellular calcium concentration
(Ceballos et al., 1999; Morley et al., 1992; Vicencio et al.,
2006; Watson et al., 2008). Estrogen is not exempt from
this effect and it was originally demonstrated in chicken
granulosa cells subjected to 17-β estradiol, that there was
an immediate (less than 5 s) 4-8 fold increase in calcium
concentration in all of the 76 cells exposed [67]. Estrogen
receptors have also been found to interact with a Gprotein on the cell membrane of osteoblasts leading to a
rapid increase in intracellular Ca2+ concentration due
distinctly to increased Ca2+ mobilisation from the endoplasmic reticulum and the formation of IP3 demonstrating
a similar mechanistic pathway as that shown during the
mobilisation of intracellular Ca2+ from the sarcoplasmic
reticulum in skeletal muscle cells by rapid testosterone
action. At this time no research has specifically investigated a non-genomic action of estrogen in skeletal muscles at either the molecular or whole muscle level.
Again, like testosterone, estrogen has demonstrated
possible positive effects in skeletal muscle, in particular
producing positive effects within the contractile machinery and even though these effects have been seen be in the
presence (hormone replacement therapy) or absence (ageing/ovariectomy) of constant exposure or non-exposure to
estrogen (17-β estradiol), the non-genomic actions of
estrogen in tissues other than skeletal muscle are similar
to those demonstrated by testosterone in skeletal muscle
cells. Therefore research is required to investigate a presence of a non-genomic action of estrogen in skeletal muscles and determine its ability to modulate force-generating
processes. It may therefore be likely that both testosterone
and estrogen are able to enhance myosin and actin binding processes due to modulations in calcium mobilisation,
resulting in a greater force and/or velocity of contraction
during acute changes in their concentrations.

Conclusion
At this time, there is small evidence of non-genomic testosterone action in human skeletal muscle and the specific
mode of action, as well as testosterone’s practical importance to athletic competition are yet to be identified. Some
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evidence points towards direct non-genomic activation of
calcium-mediated events in skeletal muscle cells, which
may modulate significant physiological responses such as
the acute modulation of force in individual fibres and
acute prevention or protection against calcium-mediated
fatigue. These responses are likely complex and mediated
by interplay between testosterone and second messengers
IP3 and calcium, which ultimately may result in simultaneous non-genomic and genomic modulations of skeletal
muscle events. However, more research is needed to elucidate the potential membrane receptor involved, as well
as the second-messenger pathway, the resulting action at
the single-cell level and the transference of testosterone to
whole muscle significance. Due to fluctuations in testosterone during the female menstrual cycle, research should
also aim to identify if there are genuine gender differences in the response or mechanism of non-genomic action of testosterone in skeletal muscle. There may be a
physiological advantage for female athletic performance
during particular phases of the menstrual cycle. As well,
polycystic ovarian syndrome and similar hyperandrogenism disorders may be a physiological advantage for specific athletes. Research to date suggests the main physiological function of non-genomic testosterone action in
skeletal muscle is the enhancement of force production
particularly in fast twitch fibres; however the actions are
likely multifaceted and further research is needed to provide evidence of a whole body performance effect in
humans.
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Key points
• Non-genomic calcium mediated events activated by
testosterone have been identified in skeletal muscle
cells.
• The non-genomic action originates at the cell membrane, is rapid in onset and is directed by second
messengers’ calcium and IP3.
• A possible action of non-genomic testosterone may
be the initiation of a more efficient contraction
through the mobilisation of calcium from the SR resulting in greater force production or velocity of
contraction in fast twitch fibres.
• Physiologically, females with menstrual disorders
that cause hyperandrogenism may have a performance advantage in events that require great force or
power production.

Non-genomic testosterone
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